Press coverage about Baxter International (NYSE:BAX) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Baxter International earned a news impact score of 0.14 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 46.2588219463122 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

Shares of Baxter International (NYSE:BAX) traded up $0.17 during trading on Tuesday, reaching $64.31. 2,576,990 shares of the company traded hands, compared to its average volume of 2,689,546. The company has a market cap of $34,896.48, a P/E ratio of 26.47, a P/E/G ratio of 2.14 and a beta of 0.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.80 and a quick ratio of 2.22. Baxter International has a one year low of $43.81 and a one year high of $66.18.

Baxter International (NYSE:BAX) last issued its earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.05. The company had revenue of $2.71 billion during the quarter, compared to the consensus estimate of $2.66 billion. Baxter International had a net margin of 9.88% and a return on equity of 15.00%. Baxter International’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.56 EPS. analysts anticipate that Baxter International will post 2.43 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, January 2nd. Investors of record on Friday, December 1st will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 1.00%. The ex-dividend date of this dividend is Thursday, November 30th. Baxter International’s dividend payout ratio is currently 34.41%.

A number of brokerages have recently issued reports on BAX. Bank of America reissued a “hold” rating on shares of Baxter International in a research report on Wednesday, November 22nd. Royal Bank of Canada reissued a “hold” rating and set a $66.00 price objective on shares of Baxter International in a research report on Wednesday, November 22nd. Stifel Nicolaus reissued a “hold” rating and set a $65.00 price objective on shares of Baxter International in a research report on Thursday, October 26th. Barclays boosted their price objective on shares of Baxter International from $70.00 to $73.00 and gave the company an “overweight” rating in a research report on Thursday, October 26th. Finally, Morgan Stanley boosted their price objective on shares of Baxter International from $59.00 to $62.00 and gave the company an “equal weight” rating in a research report on Thursday, October 26th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $67.46.

In other Baxter International news, SVP Jeanne K. Mason sold 33,350 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $65.25, for a total value of $2,176,087.50. Following the sale, the senior vice president now owns 124,609 shares in the company, valued at approximately $8,130,737.25. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Third Point Llc sold 5,000,000 shares of the business’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $64.23, for a total transaction of $321,150,000.00. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Baxter International (BAX) Given Daily Media Sentiment Rating of 0.14” was published by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.watchlistnews.com/baxter-international-bax-given-daily-media-sentiment-rating-of-0-14/1760001.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Insider Buying and Selling by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.